Our experiments suggest that this is also true in AMD: PARP1 underexpression and the SIRT1 agonist SRT1720 reduced inflammatory injury in ARPE-19 cells induced by oligomeric Aβ1-42, whereas PARP1 overexpression and the SIRT1 inhibitor nicotinamide caused the opposite effects. Here, PARP1 is linked to age-related macular degeneration.